2017
DOI: 10.1097/iae.0000000000001269
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: A significant number of patients achieved remission on infliximab therapy. The incidence of major side effects in our cohort was low.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(8 citation statements)
references
References 36 publications
0
8
0
Order By: Relevance
“…Anti-TNF-α [20] and DMARD [21] efficacy on corticosteroid sparing effect has already been described. Interestingly, after a previous relapse on DMARDs (n = 9), patients on anti-TNF-α agents had a lower corticosteroid dose at the time of treatment failure (p = 0.06).…”
Section: Discussionmentioning
confidence: 93%
See 2 more Smart Citations
“…Anti-TNF-α [20] and DMARD [21] efficacy on corticosteroid sparing effect has already been described. Interestingly, after a previous relapse on DMARDs (n = 9), patients on anti-TNF-α agents had a lower corticosteroid dose at the time of treatment failure (p = 0.06).…”
Section: Discussionmentioning
confidence: 93%
“…Among patients in the anti-TNF-α agents group who presented treatment failure (n = 14), 9 patients had previously relapsed with DMARDs. The median corticosteroid dose at the time of anti-TNFα failure was 12.5 mg/day (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). In the same patients, corticosteroid dose at the time of DMARD failure was 20 mg/day (12-30) (p = 0.06).…”
Section: Secondary Outcomesmentioning
confidence: 92%
See 1 more Smart Citation
“…There is great evidence of its efficacy in NIU, mainly BD (Sfikakis et al, 2001;Vallet et al, 2016;Fabiani et al, 2018). Maleki et al, in a small retrospective case series, achieved remission in 19 of 23 patients with active intermediate NIU refractory to at least one IMT (Maleki et al, 2017). Along the same line, Baughman et al showed a remarkable improvement in 13 out of 14 patients with several underlying causes of ocular inflammation, who were treated with infliximab after failure of classical IMT (Baughman et al, 2005) In other retrospective study, Bodaghi et al achieved a rapid control of uveitis in all 12 patients refractory to CS and IMT (Bodaghi et al, 2005).…”
Section: Infliximabmentioning
confidence: 99%
“…A retrospective case study carried out by Maleki et. al showed a reduction in infl ammation in 19 out of 23 patients with NIU [38]. Baughman, et al carried out a study on patients with ocular infl ammation and showed improvement in 13 out of 14 patients when treated with infl iximab after the failure with usual immunosuppressant therapy [39].…”
Section: Tnf- Is the Cytokine That Gets Binds To The Tumour Necrosismentioning
confidence: 99%